FDA authorizes Pfizer’s COVID-19 vaccine

UK Is First Country to Approve Pfizer's Coronavirus Vaccine. Matt Hancock, secretary of state for health of the United Kingdom, shared the news on Twitter. The government said the first batch of 800,000 vaccines will be available next week for health care workers, home care employees and people over 80. The remainder of the 40 million doses the U.K. has ordered will arrive at some point next year. According to NBC News, the Pfizer and BioNTech vaccine was authorized quicker than any other in history. It typically takes 15 to 20 years to develop similar medicines. MHRA Chief Executive Dr. June Raine assured the public that no "corners have been cut" in determining the effectiveness and safety of the vaccine. . In America, Pfizer-BioNTech and Moderna are still waiting for FDA approval

The U.S. Food and Drug Administration has granted emergency use authorization for Pfizer’s coronavirus vaccine, according to multiple news outlets.

Millions of doses are expected to be shipped right away, The New York Times reported Friday night.

The authorization marks a critical turning point in a pandemic that has taken nearly 300,000 lives in the United States. With the decision, the U.S. becomes the sixth country — in addition to Britain, Bahrain, Canada, Saudi Arabia and Mexico — to clear the vaccine. Other authorizations, including by the European Union, are expected within weeks.

A Pfizer spokesperson also confirmed the FDA’s authorization, according to reporter Kaitlan Collins.

In a speech from the Oval Office, President Donald Trump said the U.S. “achieved a medical miracle” after the FDA approved a “very safe” vaccine.

On Friday night, FDA Commissioner Stephen Hahn said the authorization “is a significant milestone in battling this devastating pandemic that has affected so many families in the United States and around the world.”

The president said the first doses will be administered in less than 24 hours and governors will decide on recipients, according to reporter Jennifer Jacobs.

On Thursday, a U.S. government advisory panel endorsed the vaccine’s widespread use, putting the country one step from launching an epic vaccination campaign against the outbreak that has killed close to 300,000 Americans.

“This is a light at the end of the long tunnel of this pandemic,” declared Dr. Sally Goza, president of the American Academy of Pediatrics.

In a 17-4 vote with one abstention, the government advisers concluded the vaccine from Pfizer and its German partner BioNTech appears safe and effective for emergency use in adults and teenagers 16 and over. That endorsement came despite questions about allergic reactions in two people who received the vaccine earlier this week when Britain became the first country to begin dispensing the Pfizer-BioNTech shot.

While there are a number of remaining unknowns about the vaccine, in an emergency, “the question is whether you know enough” to press ahead, said panel member Dr. Paul Offit of Children’s Hospital of Philadelphia. He concluded the potential benefits outweigh the risks.

The decision came as COVID-19 cases surge to ever-higher levels across the U.S., with deaths setting an all-time, one-day record of more than 3,100 on Wednesday.

Pfizer has said it will have about 25 million doses of the two-shot vaccine for the U.S. by the end of December. But the initial supplies will be reserved primarily for health care workers and nursing home residents, with other vulnerable groups next in line until ramped-up production enables shots to become widely available on demand — something that will probably not happen until the spring.

Next week, the FDA will review a second vaccine, from Moderna and the National Institutes of Health, that appears about as protective as Pfizer-BioNTech’s shot. A third candidate, from Johnson & Johnson, which would require only one dose, is working its way through the pipeline. Behind that is a candidate from AstraZeneca and Oxford University.

U.S. health experts are hoping a combination of vaccines will ultimately enable the U.S. to conquer the outbreak.

Still, experts estimate at least 70% of the U.S. population will have to be vaccinated to achieve herd immunity, the point at which the virus can be held in check. That means it could be several months before things start to get back to normal and Americans can put away their masks.

Dr. William Moss of Johns Hopkins University, who was not involved in the expert panel’s review, welcomed the outcome, saying, “Given how bad the pandemic is now, we need to move.”

Regulators in Britain and Canada have already approved the vaccine for use in their countries, and Trump and White House officials have complained for weeks that the FDA was moving too slowly.

“Americans want us to do a scientific review, but I think they also want us to make sure we’re not wasting time on paperwork as opposed to going forward with the decision,” Hahn said before the meeting Thursday.

FDA scientists issued a glowing review of the vaccine earlier in the week. Agency staffers said data from Pfizer’s ongoing study of 44,000 people showed strong protection across different age groups, races and health conditions with no major, unexpected safety problems.

The Pfizer-BioNTech shot remains experimental because that final-stage study isn’t complete. As a result, the expert panel wrestled with a list of questions that have yet to be answered.

For example, while the vaccine is more than 90% effective in blocking the symptoms of COVID-19, the FDA’s advisers stressed it is not yet clear whether it can stop the silent, symptomless spread that accounts for roughly half of all cases.

“Even though the individual efficacy of this vaccine is very, very, very high, you really as of right now do not have any evidence” that it will lower transmission, said Dr. Patrick Moore of the University of Pittsburgh. He urged Pfizer to take additional steps to answer that question.

Several of the dissenting panel members objected to authorizing the shot for 16- and 17-year-olds, given their small numbers in the study and the low risk they face from COVID-19.

Members worried, too, that Pfizer will lose its opportunity to answer critical questions once it begins offering the real vaccine to study participants who had been getting dummy shots up to now.

The company proposed gradually moving those patients to the vaccine group, with priority based on age, health conditions and other factors. Under that plan, 70-year-old participants would cross over before healthy 30-year-olds.

Pfizer must still show whether the vaccine works in children younger than 16 and in pregnant women.

On the safety front, as widespread vaccinations begin, the first recipients will be closely tracked by government health authorities, because studies in tens of thousands of people can’t detect side effects that strike 1 in a million. Hanging over the meeting were the British allergic reactions and a warning from authorities there that people with a history of serious reactions shouldn’t get the vaccine now.

Pfizer representatives said they have seen no signs of allergic reactions in their trial. But some of the FDA advisers fear the British warning will deter millions of Americans with allergies who might benefit from the COVID-19 vaccine from giving it a try and urged additional studies to try to settle the issue.

“This issue is not going to die until we have better data,” Offit said.

The Associated Press contributed to this report.